Results 91 to 100 of about 59,797 (283)
New information of dopaminergic agents based on quantum chemistry calculations
Scientific Reports, 2020 Dopamine is an important neurotransmitter that plays a key role in a wide range of both locomotive and cognitive functions in humans. Disturbances on the dopaminergic system cause, among others, psychosis, Parkinson’s disease and Huntington’s disease ...
Guillermo Goode-Romero +6 more
doaj +1 more source
Heterómeros de receptores de dopamina. Nuevos mecanismos para la regulación de la transmisión dopaminérgica [PDF]
, 2012 [spa] El Objetivo General de esta Tesis ha sido investigar la formación y función de heterómeros entre receptores de dopamina y otros receptores que puedan estar implicados en la regulación de la transmisión dopaminérgica, como receptores de galanina ...
Moreno Guillén, Estefanía
core
Ha-117 and Ha-118 are potent dopamine receptor agonists
, 1984 In-vitro studies evaluated the presynaptic dopamine receptor activities of trans-N-propyl-7,9-dihydroxyoctahydrobenzo[f]quinoline (Ha-117) and trans-N-ethyl-7,9-dihydroxyoctahydrobenzo[f]quinoline (Ha-118) using isolated field-stimulated cat right atria.
Joseph G Cannon +2 more
core +1 more source
Absence seizures: Update on signaling mechanisms and networks
Epilepsia Open, EarlyView.Abstract Absence seizures (AS) are a hallmark of genetic generalized epilepsies (GGE), characterized by brief episodes of impaired consciousness accompanied by electroencephalographic spike‐and‐wave discharges (SWDs). Traditionally attributed to cortico‐thalamo‐cortical (CTC) dysrhythmia, emerging evidence suggests a more intricate pathophysiological ...
Ozlem Akman, Filiz Onat
wiley +1 more source
Gut Medicine, EarlyView.ABSTRACT Background Dopamine (DA) exerts complex concentration‐dependent effects on gastrointestinal motility. Although its inhibitory action through D2‐like receptors is well‐established, the mechanisms underlying its excitatory effects remain elusive.
Xiao‐Li Zhang +5 more
wiley +1 more source
Do neurologists in Germany adhere to the national Parkinson's disease guideline?
Neuropsychiatric Disease and Treatment, 2011 Sabrina Schröder1, Daniel Kuessner2, Guy Arnold3, York Zöllner4, Eddie Jones5, Marion Schaefer11Institute of Clinical Pharmacology, Charité University Medicine, CCM, Berlin, Germany; 2Basilea Pharmaceutica, Basel, Switzerland;
Sabrina Schröder +3 more
doaj
Long-term outcome of patients with macroprolactinomas initially treated with dopamine agonists
, 2009 Dopamine agonists are the first line therapy for the treatment of prolactinomas. The aim of this study was to assess the outcome of macroprolactinomas during long-term follow-up after initial treatment with dopamine agonists.
Romijn, Johannes A. +3 more
core +1 more source
International Journal of Cancer, EarlyView.Chemotherapy‐induced nausea and vomiting (CINV) remains a significant clinical problem despite modern antiemetics. In particular, antiemetic strategies for emerging cancer therapies lack detailed evaluation. This randomized trial analyzed hourly CINV data for patients with early breast cancer who received either docetaxel plus cyclophosphamide (TC) or ...
Manuel Hörner +16 more
wiley +1 more source
Pharmacology of dopamine agonists in the treatment of Parkinson's disease
, 2002 There is now increasing use of dopamine agonists as effective early monotherapy in the treatment of Parkinson's disease (PD). Dopamine agonists can induce an antiparkinsonian effect through actions on either D-1-like or D-2-like dopamine receptors, and ...
Jenner, P
core
Serotonergic agonists behave as partial agonists at the dopamine D2 receptor
, 1999 RAT dopamine D2short receptors expressed in CHO cells were characterized by activation of [35S]GTPgammaS binding. There were no significant differences between the maximal effects seen in activation of [35S]GTPgammaS binding caused by dopaminergic ...
Owman, C +6 more
core +1 more source